Data Article

Data on triiodothyronine treated peroxisome proliferator-activated receptor-alpha-null mouse hearts using magnetic resonance imaging and magnetic resonance spectroscopy

Wen Zhang\textsuperscript{a,}\textsuperscript{*}, Michiel ten Hove\textsuperscript{b}, Jürgen E. Schneider\textsuperscript{b}, Kieran Clarke\textsuperscript{a}

\textsuperscript{a} Department of Physiology, Anatomy and Genetics University of Oxford, Oxford, United Kingdom
\textsuperscript{b} Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

\textbf{A R T I C L E   I N F O}

\textit{Article history:}
Received 17 May 2018
Received in revised form 12 July 2018
Accepted 3 August 2018
Available online 8 August 2018

\textbf{A B S T R A C T}

This data contain left ventricular end-diastolic volumes, end-systolic volumes, stroke volumes, ejection fractions, cardiac outputs, heart rates, phosphocreatine concentrations, adenosine 5'-triphosphate (ATP) concentrations, total creatine concentrations, citrate synthase activities and heart weights for wild-type and peroxisome proliferator-activated receptor-alpha-null mouse hearts without and with triiodothyronine treatment.

© 2018 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

\textbf{Specifications Table}

| Subject area | Medical Sciences |
|--------------|------------------|
| More specific subject area | Cardiac magnetic resonance imaging and magnetic resonance spectroscopy |
| Type of data | Figure |

\textsuperscript{*} Correspondence to: Department of Physiology, Anatomy and Genetics, University of Oxford, Sherrington Building, Parks Road, Oxford OX1 3PT, United Kingdom.
\textit{E-mail address: wen.zhang@keble-oxford.com (W. Zhang).}

https://doi.org/10.1016/j.dib.2018.08.009
2352-3409/© 2018 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
How data was acquired  
Magnetic resonance imaging, magnetic resonance spectroscopy, HPLC  

Data format  
Analyzed.  

Experimental factors  
Male mice received triiodothyronine injection for 7 days.  

Experimental features  
The effects of triiodothyronine on left ventricular functions, phosphocreatine concentrations, ATP concentrations and total creatine concentrations in peroxisome proliferator-activated receptor-alpha-null mouse hearts perfused with fatty acids free buffer were determined.  

Data source location  
University of Oxford, United Kingdom  

Data accessibility  
All data are available with this article.  

Related research article  
[1] Zhang W, ten Hove M, Schneider J E, Stuckey D J, Sebag-Montefiore L, Bia BL, Radda GK, Davies KE, Neubauer S and Clarke K. Abnormal cardiac morphology, function and energy metabolism in the dystrophic mdx mouse: an MRI and MRS study. J Mol Cell Cardiol. 2008 45:754-60.  

Value of the Data  
- The data can be used to further investigate whether the cross-talk between peroxisome proliferator-activated receptor-alpha and triiodothyronine signaling pathways in vitro happens in hearts in vivo.  
- The data can be used to investigate how peroxisome proliferator-activated receptor-alpha and triiodothyronine regulate mitochondrial contents in hearts.  
- The data can be used to investigate the role of peroxisome proliferator-activated receptor-alpha in left ventricular dysfunction in human non-alcoholic fatty liver disease and in pharmaceutical area.  

1. Data  
Triiodothyronine treatment causes abnormal decrease of left ventricular stroke volumes, phosphocreatine concentrations and ATP concentrations associated with abnormal increase of heart weights and citrate synthase activities in peroxisome proliferator-activated receptor-alpha-null mouse hearts (Fig. 1).  

2. Experimental design, materials, and methods  
Cardiac magnetic resonance imaging, magnetic resonance spectroscopy, total creatine concentrations and citrate synthase activities as previously described [1] were quantified in male wild-type (129S6/SvEv) (n = 12), age-matched male peroxisome proliferator-activated receptor-alpha-null mice (129/Sv strain background) (n = 12), age-matched triiodothyronine-injected male wild-type (n = 15) and age-matched triiodothyronine-injected male peroxisome proliferator-activated receptor-alpha-null mice (n = 13) at the age of 8 months old. All the procedures were approved by the Animal Ethics Review Committees, University of Oxford, and by the Home Office, United Kingdom. Triiodothyronine-injected wild-type and peroxisome proliferator-activated receptor-alpha-null mice were injected 3,3',5-triiodo-L-thyronine solution (0.2 mg per kg body weight per day) for 7 consecutive days intraperitoneally. Differences between two groups were analyzed by Student’s t-test.
Fig. 1. Magnetic resonance imaging and spectroscopy data. A: Representative images at end-diastole. Scale bar = 2 mm. PPARα-null, peroxisome proliferator-activated receptor-alpha-null; T3, triiodothyronine. B: Quantified magnetic resonance imaging data (n = 6 for wild-type, n = 6 for PPARα-null, n = 8 for T3-treated wild-type, and n = 6 for T3-treated PPARα-null). LV EDV, left ventricular end-diastolic volume; ESV, end-systolic volume; SV, stroke volume; EF, ejection fraction; CO, cardiac output. Stroke volume = end-diastolic volume – end-systolic volume; ejection fraction = stroke volume/end-diastolic volume; cardiac output = stroke volume x heart rate. C: Representative spectra. Pi, inorganic phosphate; PCr, phosphocreatine; γ, α and β ATP, γ, α and β phosphate groups of adenosine-5’-triphosphate. D: Quantified magnetic resonance spectroscopy, total creatine, and citrate synthase activities data (n = 6 for wild-type, n = 6 for PPARα-null, n = 7 for T3-treated wild-type, and n = 7 for T3-treated PPARα-null). ΔGATP, free energy available from ATP hydrolysis; gww, gram wet weight. Data are means ± SEM. * P < 0.05 vs. wild-type; † P < 0.01 vs. wild-type; ‡ P < 0.05 vs. T3-treated wild-type; § P < 0.01 vs. T3-treated wild-type; ¶ P < 0.05 vs. PPARα-null, # P < 0.01 vs. PPARα-null.
Acknowledgments

Wen Zhang acknowledges Clarendon Scholarships from University of Oxford and Hong Kong Oxford Scholarship for supporting her DPhil studies.

Funding resources

This work is part of Wen Zhang’s DPhil thesis and was supported by the British Heart Foundation (grant reference PG/07/030/22667).

Transparency document. Supporting information

Transparency data associated with this article can be found in the online version at https://doi.org/10.1016/j.dib.2018.08.009.

Reference

[1] W. Zhang, M. ten Hove, J.E. Schneider, D.J. Stuckey, L. Sebag-Montefiore, B.L. Bia, G.K. Radda, K.E. Davies, S. Neubauer, K. Clarke, Abnormal cardiac morphology, function and energy metabolism in the dystrophic mdx mouse: an MRI and MRS study, J. Mol. Cell Cardiol. 45 (2008) 754–760.